Svanerud J, et al. Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention. 2018;14:806-814.
Ford T, et al. CorMicA Trial. 2018; 72(23): 2841-55 with online appendix.
Kunadian V, Chieffo A et al. EHJ & Eurointervention 2020: ehaa503. DOI:10.1093/eurheartj/ehaa503.
Tonino PA, et al. Angiographics versus functional severity of coronary artery stenoses in the FAME study: Fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010; 55:2816-21.
De Bruyne B, et al. FFR Guided PCI versus Medical Therapy in Stable Coronary Disease, NEJM. 2012; 367 (11): 991-1001.
Volcano Corp. Verrata‡ guidewire and PrimeWire Prestige‡ Plus guidewire IFUs, Opsens Inc. OptoWire‡ guidewire and OptoWire‡ II guidewire IFUS, ACIST Medical Systems. Navvus‡ Microcatheter IFU, Boston Scientific Corporation. Comet‡ guidewire IFU.
Coroventis‡ CoroFlow‡ Cardiovascular System IFU.
QUANTIEN™ Measurement System IFU.
OPTIS™ Measurement System IFU
Data on file at Abbott.
Zhang J, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll Cardiol. 2018;72(24):3126-3137. doi: 10.1016/j.jacc.2018.09.013.
Hong M, et al. IVUS-XPL 5 Year Outcomes, TCT 2019.
Jones et al. JACC Cardiovascular Interventions, 2018, vol 11 (14). “Angiography Alone Versus Angiography Plus Optical Coherence Tomography to Guide Percutaneous Coronary Intervention – Outcomes From the Pan-London PCI Cohort”.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.